Evidence Paper Review

 Quick Explanation Copied

 Long Explanation

What the census found

The paper is a cross-sectional inventory of repurposed FDA-approved agents in the AD pipeline using ClinicalTrials.gov (data cut-off February 27, 2020) plus a cross-check of the EUCTR Registry-based pipeline census methods. Headline counts: 53 trials, 58 agents (50 unique). Phase III: 15 agents/12 trials (~one-third of all Phase III AD trials); Phase II: 33/32 (44% of Phase II); Phase I: 10/9 (33%). Repurposing trials grew 89% from 2016 to 2020, with DMT repurposing trials up 180% while symptomatic repurposing fell 67% Five-year repurposing growth figures.

The authors interpret the shift as a field-level pivot: repurposed agents are now overwhelmingly pursued as disease-modifying (78% DMT overall; 79% of 2020 repurposed trials vs 54% in 2016). Origin areas: 20% hematologic-oncologic, 18% cardiovascular, 14% psychiatric, 12% antidiabetic, 10% neurologic, 26% other Therapeutic-area distribution of repurposed agents.

Economics and sponsorship: the structural core

The most insightful observation is that 79% of repurposing trials are sponsored by Academic Medical Centers and only 9% by biopharma — the inverse of the broader AD pipeline (46% industry-funded) Sponsor distribution findings. The authors correctly attribute this to generic-drug IP weakness and document mitigation strategies: ultra-low dosing (AGB101 levetiracetam at 1/15th the anticonvulsant dose; HOPE4MCI at 1/10th), novel formulations (insulin glulisine rapid- vs long-acting; montelukast buccal film), and combinations (cromolyn+ibuprofen; losartan+amlodipine+atorvastatin) Intellectual property strategy examples.

Critical assessment

Reported observations are solid; author interpretations warrant skepticism. (1) The 39% US vs ~10% EU divergence is partly an artifact — 43% of EUCTR repurposing trials had stale "ongoing" status while ClinicalTrials.gov showed completed/terminated, a registry-quality problem the authors themselves flag EUCTR status discrepancy finding. (2) The "78% DMT" claim depends on the authors' own MOA assignments, which they admit is "arbitrary" for pleiotropic drugs; many "other MOA" DMTs (22 of 27 in Phase II) rest on thin preclinical bridges rather than validated amyloid/tau engagement. (3) The paper is descriptive — no trial outcome data, no effect sizes, no hypothesis tests — appropriate for a census but limited in inferential value. (4) Underlying trial data later accumulate negative results for several agents; a 2020 snapshot cannot forecast 2021-2026 trial outcomes, so the growth trend should not be read as evidence of clinical promise. (5) undisclosed author conflicts are extensive (consultations across ~30 pharma companies), a potential framing bias for what counts as a "promising" pipeline agent, though the census methodology itself is transparent Author conflict-of-interest disclosure. (6) Later work shows repurposing candidate selection is far from settled: Delphi consensus and LLM/network approaches propose largely non-overlapping candidate sets (e.g., zoster vaccine, riluzole, sildenafil vs network-derived chenodiol/TUDCA, arundine), indicating the pipeline census captures only candidate-trial activity, not candidate-worthiness Delphi consensus repurposing prioritiesNetwork pharmacology repurposing validation.

Verdict: a rigorous, transparent, well-executed registry census (methodology replicated across five annual pipeline reports) that remains the reference picture of early-2020 AD repurposing activity. Its claims are descriptive and registry-bounded; the DMT classification and US-EU comparison are the weakest links. Confidence: moderate — high for the counts, low for downstream interpretations.

Track 2025 Trial OutcomesRepurposing Cost EvidencePhase III Agent Table

Author Review: Jeffrey CummingsAuthor Review: Garam LeeAuthor Review: Justin Bauzon

 BGPT Paper Review

Study Novelty

First systematic quantification of repurposing specifically within the AD pipeline, building on the authors' own 2016-2019 census series; incremental extension of established methodology rather than a new scientific concept.

Scientific Quality

Transparent, replicable registry methodology with consistent cross-year classification; but purely descriptive, no inferential statistics, subjective MOA assignments, snapshot dated, and heavy author pharma conflicts despite declared study funding neutrality.

Study Generality

Findings are AD-specific and time-bound, but the framework (registry census + MOA + sponsor analysis) generalizes to other disease areas and informs repurposing policy broadly.

Study Usefulness

Directly actionable for funders, trial designers, and policy analysts: quantifies the academic-sponsorship bottleneck and documents concrete IP strategies that still guide repurposing program design.

Study Reproducibility

Explanatory Depth

Describes the pipeline landscape and economic drivers well, but mechanistic explanations for why specific repurposed agents were chosen rest on literature citations rather than new causal analysis.